Form 4: Praxis Precision Medicines CFO Timothy Kelly Reports Stock and Option Awards

Chief Financial Officer Timothy Edwin Kelly of Praxis Precision Medicines reports the acquisition of restricted stock units and stock options.

Summary

• Timothy Edwin Kelly, CFO of Praxis Precision Medicines, filed a Form 4 detailing changes in beneficial ownership.
• On July 29, 2024, Mr. Kelly was awarded 7,800 restricted stock units (RSUs), each representing a contingent right to receive one share of Praxis Precision Medicines' common stock.
• These RSUs vest in equal annual installments over a four-year period starting January 12, 2025, contingent upon continued service.
• Mr. Kelly also acquired options to purchase 36,400 shares of common stock at an exercise price of $56.94.
• 7/48ths of these options vested on July 29, 2024, with the remaining shares vesting in substantially equal monthly installments over the following 41 months, also subject to continued service.
• Following these transactions, Mr. Kelly directly owns 12,140 shares of common stock and options for 36,400 shares.
• The options expire on July 29, 2034.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of RSUs and stock options aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the reporting person's continued service, suggesting an expectation of continued employment.

Industry Context

Stock and option awards are a common practice in the pharmaceutical industry to attract and retain key executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation packages for CFOs in the biotechnology industry typically include a mix of stock options, restricted stock units, and performance-based awards.
• The vesting schedules and grant sizes are generally comparable to those offered by similar-sized companies in the sector, such as BioMarin Pharmaceutical or Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates